Canaday D J, Regine W F, Mohiuddin M, Zollinger W, Machtay M, Lee J, Schultz D, Rudoltz M S
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, USA.
Radiat Oncol Investig. 1999;7(1):42-8. doi: 10.1002/(SICI)1520-6823(1999)7:1<42::AID-ROI6>3.0.CO;2-W.
Recent reports have suggested that pretreatment hemoglobin level (Hgb) is significantly associated with local control (LC) and overall survival (OS) in patients with T1 and T2 squamous cell carcinoma of the glottic larynx. To further evaluate the association of pretreatment Hgb level and other factors with outcome, we performed a retrospective review limited to patients with T1 squamous cell carcinoma of the glottic larynx treated with external beam radiation therapy. One-hundred thirty-nine patients with T1 squamous cell carcinoma of the glottic larynx were analyzed. Median follow-up was 5 years (range 2-22). Median pretreatment Hgb was 14.4 gm/dl (range 8.2-17.2). The following parameters were analyzed for their impact on LC, OS, and disease specific survival (DSS): age; gender; pretreatment Hgb; tumor grade; anterior commissure involvement; field size; total dose; dose per fraction; and overall treatment time. Five-year actuarial LC was 84%. Pretreatment Hgb was not a significant predictor for LC when assessed as a continuous variable (P = 0.38), nor as a dichotomous variable with a cutoff at 13 gm/dl. Local control was 82% for patients with Hgb >13 vs. 92% for Hgb < or = 13 (P= 0.13). No other factor was significant for LC. Five-year actuarial OS was 74%. Univariate analysis revealed that, pretreatment Hgb, total dose, and patient age were significant factors for OS. Overall survival was 78% for patients with pretreatment Hgb > 13 gm/dl vs. 68% for patients with Hgb < or = 13 gm/dl (P = 0.004). Overall survival was 77% for patients treated with > 66 Gy vs. 67% for those treated with < or =66 Gy (P = 0.0013), and 80% for patients < or =61 years as opposed to 69% for patients older than 61 years (P = 0.017). Multivariate analysis revealed that only age (P = 0.014) and Hgb concentration (P = 0.001) retained significance. Five-year actuarial DSS was 92%. Pretreatment Hgb was not a prognostic factor for DSS, nor were any other analyzed factors. Pretreatment Hgb is not a significant prognostic factor for LC in patients with T1 squamous cell carcinoma of the glottic larynx, but it does predict for a poorer OS without affecting DSS. This suggests that patients with lower pretreatment Hgb may have confounding medical problems that detract from their overall survival.
近期报告表明,声门T1和T2期鳞状细胞癌患者的治疗前血红蛋白水平(Hgb)与局部控制(LC)及总生存期(OS)显著相关。为进一步评估治疗前Hgb水平及其他因素与预后的关系,我们对接受外照射放疗的声门T1期鳞状细胞癌患者进行了一项回顾性研究。分析了139例声门T1期鳞状细胞癌患者。中位随访时间为5年(范围2 - 22年)。治疗前Hgb中位数为14.4 g/dl(范围8.2 - 17.2)。分析了以下参数对LC、OS和疾病特异性生存期(DSS)的影响:年龄;性别;治疗前Hgb;肿瘤分级;前联合受累情况;照射野大小;总剂量;每次分割剂量;以及总治疗时间。5年精算LC率为84%。当将治疗前Hgb作为连续变量评估时,它不是LC的显著预测因素(P = 0.38),以13 g/dl为临界值作为二分变量评估时也不是。Hgb >13的患者局部控制率为82%,而Hgb≤13的患者为92%(P = 0.13)。没有其他因素对LC有显著影响。5年精算OS率为74%。单因素分析显示,治疗前Hgb、总剂量和患者年龄是OS的显著因素。治疗前Hgb > 13 g/dl的患者总生存期为78%,而Hgb≤13 g/dl的患者为68%(P = 0.004)。接受> 66 Gy治疗的患者总生存期为77%,而接受≤66 Gy治疗的患者为67%(P = 0.0013),年龄≤61岁的患者为80%,而年龄大于61岁的患者为69%(P = 0.017)。多因素分析显示,只有年龄(P = 0.014)和Hgb浓度(P = 0.001)具有显著性。5年精算DSS率为92%。治疗前Hgb不是DSS的预后因素,其他分析因素也不是。治疗前Hgb不是声门T1期鳞状细胞癌患者LC的显著预后因素,但它确实预示着较差的OS,而不影响DSS。这表明治疗前Hgb较低的患者可能存在影响其总生存期的混杂医学问题。